pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›MIRABEGRON
drug
save

MIRABEGRON

updated 3mo ago
by Lupin Ltd
community read0 votes

🐶 often sniffed alongside

top 5
  • tagApproval8 co-mentions · 4 sources
  • drugmirabegron ER4 co-mentions · 4 sources
  • tagSmall Molecule4 co-mentions · 4 sources
  • drugmirabegron SR4 co-mentions · 4 sources
  • companyLupin Ltd2 co-mentions · 2 sources

all catalysts(0)

nothing on the calendar yet

Trials studying MIRABEGRON

  • phase3A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivityactive not recruitingn=7
  • phase4Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)completedn=888
  • phase3A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.completedn=1,887
  • phase3A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladdercompletedn=2,030
  • phase3Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladdercompletedn=2,336
  • phase3A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladdercompletedn=2,149
  • phase3Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladdercompletedn=2,792
  • phase4A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladdercompletedn=249
more trials →

News(0)

no news has mentioned this drug yet

brand
MIRABEGRON
generic
MIRABEGRON
Data sources
ClinicalTrials.gov
last refreshed 39m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?